Abstract. Peptide binding to HLA molecules is a critical step in induction and regulation of T-cell mediated immune responses. Because of combinatorial complexity of immune responses, systematic studies require combination of computational methods and experimentation. Most of available computational predictions are based on discriminating binders from non-binders based on use of suitable prediction thresholds. We compared four state-of-the-art binding affinity prediction models and found that nonlinear models show better performance than linear models.
Introduction
Major histocompatibility complex (MHC) molecules present peptides, derived from antigens and host proteins, on the cell surface. The recognition of presented peptides by TCD8 + cells is necessary for recognition of infected or pathologically mutated cells and induction of cellular immune responses and subsequent elimination of tumors and infected cells. Human MHC is known as the human leukocyte antigen (HLA). Antigen processing and presentation involves primarily three steps: proteasomal cleavage, translocation of cleaved fragments by transporter associated with antigen processing, and HLA-peptide binding. The HLA/peptide binding is by far the most discriminative step: natural prevalence of HLA-binding peptides is in the range of 0.1-5% for any given protein of which some 20% remain functionally relevant [1, 2] . Therefore, computational prediction and modeling of HLA/peptide binding can greatly facilitate peptide screening, with tremendous savings in time and experimental effort.
The HLA peptide binding prediction can be approached as simple classification problem of discriminating binders from non-binders. However, peptide binding is necessary but it does not guarantee an immune response. A binding affinity metric like inhibition concentration (IC 50 ) of a standard probe quantifies HLA/peptide binding. Given a large number of binding data recently made available [3] we have extended the approach by studying peptide binding as a regression problem.
Many different attempts have been made to predict MHC peptide binding. There are primarily three approaches: by structure modelling, data-driven using peptide sequences and their binding affinities, or by the combination thereof. Sequence-based approaches can be further categorized into motif/profile based methods [4] [5] [6] [7] [8] [9] and machine learning methods which use Artificial Neural Networks (ANN) [10, 11] , Hidden Markov Models (HMM) [12] , or Support Vector Machines (SVM) [13] [14] [15] [16] [17] [18] [19] . An example of combined method is the adaptive double threading [20] . The prediction methods have been compared for accuracy of classification (binders vs. non-binders) [3, 21, 22] . However different data sets are used to build models and evaluation data vary between different studies making it intrinsically difficult to compare predictor performance.
Recently, a comprehensive experimental relative binding affinity analysis of a complete overlapping peptide library derived from the tumor-associated antigen survivin [23] was reported for eight different types of HLA class I molecules. Also, a large data set of peptide binding affinities became available at the Immune Epitope Database and Analysis Resource (IEDB, www.immuneepitope.org) [3] . Combining these two data sets, we analysed the factors that affect accuracy of prediction models and explored the correlation of peptide binding and immunogenicity. The results of this study provide an improved understanding of the prediction systems design issues and their use for identification of HLA-binding peptides and T-cell epitopes.
Materials and Methods
Four different prediction methods were used in this study. Support Vector Regression (SVR) and epitope information were used to build a regression model to predict HLA-peptide binding affinities using the first of the data sets. The three models used at IEDB, namely ANN and two matrix methods were used as comparison predictors. We defined prediction performance criteria to enable fair comparisons between models. Specifically, we used match curve area and correlation coefficient to compare model performance.
Datasets
Survivin, a member of the apoptosis inhibitor protein family, is one of a limited number of shared tumor-associated antigens that is over-expressed in the majority of human cancers. There is an intense interest in using survivin as a target for therapeutic CTL response. Bachinsky et al. [23] Another set of proteins that has been comprehensively studied in T-cell responses are HIV proteins. We analyzed all HIV protein T-cell epitopes available in the HIV molecular immunology database (www.hiv.lanl.gov/content /immunology). In addition, we analysed mutations of a small set of HLA-restricted CD8 + T-cell epitopes. Peters et al. [3] have made public a set of 48,828 quantitative peptide-binding affinity measurements relating to 48 different mammalian MHC class I alleles. They used this data to establish a set of predictions with one neural network method (IEDB ANN) and two matrix-based prediction methods (IEDB SMM and IEDB ARB) and compared them with other available online predictors. In this study, we only used eight nonamer datasets of the eight HLA alleles of interest in this study. The data set (which we denote as the IEDB data set) was downloaded from (mhcbindingpredictions.immuneepitope.org).The datasets used in this study were: A*0101 (1157 peptides), A*0201 (3089), A*0301 (2094), A*1101 (1985), A*2402 (197), B*0702 (1262), B*0801 (708), and B*1501 (978).
SVM regression model and peptide coding using extra epitope information
The SVM is firmly based on statistical learning theory. It can be used to solve both classification and regression problems by optimizing given generalization bounds. Its regression form (SVR) is based on a loss function that ignores errors within a certain distance of the true value (we use the ε-insensitive loss function). In SVMs data is implicitly projected into a high-dimensional feature space using a kernel function. We employed the Gaussian kernel,
, where x and z are two samples and σ is a kernel parameter. The Gaussian kernel requires peptides to be represented as numerical vectors. A sparse orthogonal coding was used to represent peptides, with each amino acid encoded by 20 bits (19 bits set to zero and 1 bit set to one). Hence, a nonamer is represented in a 180-dimensional space. The coding vector was extended by nine positions encoding the shape of the binding motif for each studied allele. The final coded peptide vector had 189 elements and we refer to it as the extended sparse coding.
IEDB Prediction models
IEDB ANN, SMM and ARB prediction models are used by IEDB website and all three methods predict the quantitative binding affinity. The ANN is a nonlinear model and the other two generate scoring matrices. They have been used as benchmarking predictions [3] and we compared the SVR model performance with them.
Performance evaluation methods
To compare two classifiers discriminating binders vs. non-binders, area under ROC (Receiver operating characteristic curve; the AUC value) compares overall performance of classifiers and does not require a decision threshold to be determined. For regression, the correlation coefficient between predicted and true binding affinities were used. To assess potential epitopes/binders along protein sequences, we used "match curve" plots of the number of true binders in the top N ranked predicted affinities (y-axis) vs. N (x-axis). If most of true epitopes can be found within a short list of top ranked predicted binders, the prediction system is very useful for screening epitopes along protein sequences.
Study design
This study has three parts designed to understand prediction systems for HLAbinding peptides, the relationship between binding affinities and known T-cell epitopes for survivin and selected HIV proteins, and the relationship of natural epitopes and their mutants.
SVR HLA-binding predictor
The Gaussian kernel and the extended sparse coding SVR were combined with the IEDB datasets to build a regression model for binding affinity prediction for each HLA allele. Since vast majority of IC 50 values from the IEDB database for the eight HLA alleles are within 1 to 50,000 nM, we transformed the binding affinities to the range of 0 and 1 by using 1 − log(binding affinity)/ log(50000) as described in [25] .
The model building was done using single-level five-fold cross-validation for each allele. We used the test data in each run to tune regularization and kernel parameters. We got five different regression models from the cross-validation process. We repeated the five-fold cross-validation five times. Regression performance was reported as the mean value of correlation coefficients from the five runs. In addition, we chose the models from a single cross-validation run which gave the best cross-validation performance. These five regression models were used as a committee for the corresponding single allele to get predicted binding affinity values for all yet unseen peptides.
Prediction of HLA-binding peptides in survivin protein
The comprehensive experimental relative binding affinity analysis of the complete survivin peptide set presented an opportunity to evaluate how different predictive models perform against an independent data set representing a complete protein. We applied our regression model on the survivin dataset and retrieved prediction results from the IEDB prediction servers to compare their performances. Comparison was based on the correlation coefficient calculated from the predicted binding affinities and the experimentally measured relative binding affinities.
Prediction of T-cell epitopes on HIV proteins and Survivin protein
We used the SVR model to predict binding affinities for known T-cell epitopes on HIV proteins and survivin within the eight alleles. When a known epitope is longer than a nonamer, we took the highest binding affinity of all possible nonamers within the epitope as its binding affinity. We also did one site mutagenesis on eight T-cell epitopes of HIV proteins and survivin in order to compare their affinities to corresponding ascendant epitopes and find mutation patterns.
Results
4.1 Cross-validation performance on the eight HLA-alleles Table 1 shows the correlation coefficient (with standard deviation) of SVR models on the eight HLA-alleles using cross-validation. Most of correlation coefficient performances are satisfactory except for the B*0801 allele. Figure 1 shows the binding affinity distributions of data sets for HLA-A*0201, A*2402 and B*0801 and the horizontal line in each subplot denotes the binding affinity value, log 10 (500). From the analysis of experimental data from [3] , log 10 (500) was taken as a threshold for binder and non-binder, which means that for a peptide with log 10 (IC 50 ) value less than log 10 (500) it should be treated as a binder. Although the threshold, log 10 (500), is arbitrary, it enables objective separation of binders from non-binders. From Figure 1 , it is clear that there are very few samples (only 21) with binding affinities less than the threshold versus the total around 700 samples for B*0801 allele. For A*2402 alleles, there are only 197 samples in total, but the predictor performance is superior to that of B*0801. A possible explanation is that the dataset is more balanced. For the A*0201 allele the dataset is slightly unbalanced, however, there are still about 1000 samples with IC 50 values below the binding threshold. This observation holds for other alleles. More samples with stronger binding affinities seem to imply better prediction performance. 
Prediction of binding affinity along survivin protein sequence
For each of the eight HLA alleles we calculated the correlation coefficient between experimental binding values and predicted binding affinities. log 10 (IC 50 ) values of all nonamers in the survivin sequence were predicted using IEDB ANN, SMM and ARB prediction tools (tools.immuneepitope.org/analyze/html/ mhc binding.html). Figure 2 illustrates performance differences between models (HLA-A*2402 ANN method is not available from the IEDB web server). IEDB ANN is generally superior, followed by SVR. SMM and ARB show similar performance inferior to the other two.
For screening potential epitopes/binders in long protein sequences, it is useful to look at the match curve to assess how many peptides are typically required to test to identify all true epitopes/binders. Figure 3 shows the match curves for the eight alleles using the IEDB ANN and our SVR models using experimental data for survivin peptides. For A*0101 there are no binders according to the experimental settings in [23] and for A*2402 results for IEDB ANN are unavailable. The classification performance of ANN and SVR is very similar. For A*0201, A*0301 and B*0801, SVR is slightly better than the IEDB ANN. Most of experimentally determined binders are within a few numbers of the predicted top peptides. The worst performance by this measure is for the A*2402 allele, where 19 of 23 binders are within predicted top 65 peptides. Figure 4 displays the predicted binding affinities, log 10 (IC 50 ), using SVR for known HIV T-cell epitopes. The upper horizontal line indicates log 10 (5000) and followed by log 10 (500) and log 10 (50). In [10] , a peptide with log 10 (IC 50 ) less than log 10 (5) is a very good binder; good binder with affinity between log 10 (5) and log 10 (50); intermediate binder between log 10 (50) and log 10 (500) and low affinity binder between log 10 (500) and log 10 (5000). In B*1501, all epitopes are low affinity binders. In B*0801 predictions are not informative, reflecting poor training set. For other alleles, T-cell epitopes show a broad range of binding affinities, most of which are between log 10 (50) and log 10 (5000) .
Predictions of T-cell epitopes
We compared the predicted binding affinities with experimental data for known survivin T-cell epitopes, shown in Table 2 . Both known T-cell epitopes have moderate binding affinity. The 96-104 epitope is the third highest binder to A*0201 while 20-28 is the second highest binder to A*2402 of all survivin peptides [23] . Predicted binding affinities are approximately within 2-fold concentration of their experimental affinities indicating excellent correlation. Table 3 shows natural epitopes and their in silico mutant versions with the highest predicted binding affinities. The affinity change varies from 2 to 10 fold. For A*0201, the mutant happens at the second position from T to M or L; for A*0101, it is at the ninth position from E to Y; for A*1101, at the seventh position from C to F; and for A*2402, at the second position from T to Y. This example illustrates a possible vaccine engineering applications with modified peptides. In a successful case study of immunotherapy with modified survivin 96-104 peptide LMLGEFLKL in a liver metasthasis of pancreatic cancer the result was a complete remission of metasthasis [26] . Table 4 shows in silico mutations of natural HIV epitopes and their mutants with the highest binding affinities. 
Conclusions
IEDB ANN model is the best among the four models, followed by the SVR model. The predictions by SMM and ARB models are inferior to them. The two non-linear methods produced more accurate predictions than two linear methods. We also found that, provided that training sets are representative, the more training samples result in a better prediction performance. IEDB ANN and SVR models performed similarly in scanning potential binders when tested on survivin sequence. Both true epitopes were within top 2.5% of predicted binders. Therefore, in silico models can save significant experimental time and costs in screening potential targets. By analyzing predicted binding affinities of known HIV T-cell epitopes, we found that the range of binding affinities varies for different alleles; and the range of binding affinities include high, moderate, and low affinity. Most of the survivin epitopes are intermediate affinity binders compared to their one-site mutated descendants, some of which are high-affinity binders. The change of IC 50 varies from 2 to 10 fold for mutated epitopes and most of them were at epitope anchors or auxiliary anchors. These phenomena indicate that high binding affinity binding and immunogenicity are not necessary correlated. Table 4 . Differences between natural HIV epitopes and their mutants resulting in improved binding affinity.
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Binding affinity alone is not sufficient to describe the interaction between HLA allele molecules and peptides. Other factors like dissociation rate or stability of each complex are also the determinants of the interaction. Classification of interaction into binders and non-binders only is not informative of immunogenic properties of peptides. Known survivin-derived T-cell epitopes are low affinity binders to their respective HLA molecules.
Most of its known T-cell epitopes of tumor antigen survivin are low affinity binders, which might offer an explanation for lack of response to antigens in cancer patients, self-tolerance, and subdominance [23] . It is unclear which epitopes within a given tumor-associated antigen should be selected to circumvent tolerance and hence serve as the best target in anti-tumor vaccination. One challenge for vaccine design is to enhance the immunogenicity of weak antigens and prevent silencing of active T-cell clones. One possible strategy is to optimize tumor-associated antigen epitope analogs for priming. The in silico mutation analysis demonstrated that the optimization should target mainly anchor or auxiliary anchor positions.
